이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Brooks Laboratories 대차 대조표 상태

재무 상태 기준 확인 4/6

Brooks Laboratories 의 총 주주 지분은 ₹655.9M 이고 총 부채는 ₹50.4M, 이는 부채 대 자기자본 비율을 7.7% 로 가져옵니다. 총자산과 총부채는 각각 ₹904.5M 및 ₹248.6M 입니다. Brooks Laboratories 의 EBIT는 ₹14.5M 이며 이자보상배율은 1.7 입니다. ₹6.9M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

8.6%

부채 비율

₹56.42m

부채

이자 보상 비율	2.1x
현금	₹6.93m
주식	₹655.85m
총 부채	₹248.60m
총 자산	₹904.45m

최근 재무 상태 업데이트

Recent updates

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Sep 28

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Jun 10

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Feb 22

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Dec 08

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Jul 07

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Jan 05

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Sep 22

재무 상태 분석

단기부채: BROOKS 의 단기 자산 ( ₹310.5M )이 단기 부채( ₹230.5M ).

장기 부채: BROOKS 의 단기 자산( ₹310.5M )이 장기 부채( ₹18.1M ).

부채 대 자본 내역 및 분석

부채 수준: BROOKS 의 순부채 대 자기자본 비율( 6.6% )은 satisfactory로 간주됩니다.

부채 감소: BROOKS 의 부채 대 자기자본 비율은 지난 5년간 28.9% 에서 7.7% 로 감소했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BROOKS 현재 무료 현금 흐름을 기준으로 1년 미만의 cash runway를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 16.2 %의 역사적 비율로 계속 감소할 경우 BROOKS 의 현금 활주로는 1년 미만입니다.

Brooks Laboratories 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Recent updates

Brooks Laboratories Limited Announces Board Appointments

New minor risk - Share price stability

High number of new and inexperienced directors

Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024

First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024)

Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024

New minor risk - Share price stability

Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023)

Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023)

Brooks Laboratories Limited Announces Director Appointments

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023

New minor risk - Shareholder dilution

Brooks Laboratories Limited Approves the Appointment of Bhushan Singh Rana as an Additional Director (Executive)

First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023)

Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Brooks Laboratories Limited Appoints Durga Shankar Maity as Additional Director

Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022)

Brooks Laboratories Limited Appoints Kaushalya Singh as a Whole Time Director of the Company

Brooks Laboratories Limited Announces Resignation of Atul Ranchal as Chairman, Effective on November 23, 2022

Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?

Brooks Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022)

Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?

Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021)

Jyoti Sancheti Resigns as Company Secretary & Compliance Officer of Brooks Laboratories Limited, with Effect from 7 June, 2022

Brooks Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Brooks Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?

Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021)

Less than half of directors are independent

Technical Director & Whole Time Director Suresh Garg has left the company

Insufficient new directors

Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?

Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020)

Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020)

New 90-day low: ₹58.60

Brooks Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt

New 90-day high: ₹73.20

New 90-day high: ₹71.75

New 90-day high: ₹68.75

Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt

Brooks Laboratories Limited to Report Q4, 2020 Results on Jul 30, 2020

First quarter earnings released

New 90-day high: ₹44.65

Brooks Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

Full year earnings released - ₹13.84 loss per share

New 90-day high - ₹37.80

Full year earnings released - ₹13.84 loss per share

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기